Printed from Voxsanity (voxsanity.com.au) — NCT01804686 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
AI generated eligibility summary.
Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source.
How we use AI
Who might be able to join this trial:
People who are currently taking part in another ibrutinib clinical study that is considered complete, and who have been taking ibrutinib alone for at least 6 months (people with less than 6 months may still be considered but would need more frequent safety check-ins at the start).
People who were originally assigned to a comparison treatment in an ibrutinib study and are now switching over to ibrutinib (the 6-month minimum does not apply in this situation).
People currently enrolled in a specific study called PCI-32765LYM1002 who are actively receiving either ibrutinib alone or ibrutinib combined with a medicine called nivolumab.
People whose treating doctor believes the benefits of continuing ibrutinib (alone or with nivolumab) outweigh the potential risks.
People who agree to use effective contraception as required by the trial protocol.
People whose pregnancy test (blood or urine) comes back negative at the screening stage.
Who may not be able to join:
People who need to take blood-thinning medicines such as warfarin or similar vitamin K antagonist medications.
People who need to take certain strong medications that affect how the body processes drugs (known as strong CYP3A4/5 inhibitors), unless the trial sponsor has previously given approval (confirm with trial site).
People who have any health condition or personal circumstance that, in their doctor's opinion, could put them at significant risk, affect the study results, or seriously interfere with their ability to take part.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Contact this trial
Principal Investigator: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Australian sites
Royal Adelaide Hospital, Adelaide,
John Fawkner Cancer Trial Centre, Coburg,
Concord Hospital, Concord,
Austin Health, Heidelberg,
Peter MacCallum Cancer Centre, Melbourne,
Royal Perth Hospital, Perth,
Alfred Hospital, Prahran,
Adventist Health Care Limited trading as San Clinical Trials Unit, Wahroonga,
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Voxsanity
Clinical trials and treatments, explained plainly · voxsanity.com.au
Date:
To: My Doctor
Re: Clinical trial enquiry
I am writing to enquire about the following clinical trial which may be relevant to my care:
Trial: NCT01804686
Sponsor: Janssen Research & Development, LLC
Phase: Phase 3
Status: Recruiting
Condition: Leukaemia
More information: https://clinicaltrials.gov/study/NCT01804686
Eligibility summary (AI generated)
Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.
Who might be able to join this trial:
People who are currently taking part in another ibrutinib clinical study that is considered complete, and who have been taking ibrutinib alone for at least 6 months (people with less than 6 months may still be considered but would need more frequent safety check-ins at the start).
People who were originally assigned to a comparison treatment in an ibrutinib study and are now switching over to ibrutinib (the 6-month minimum does not apply in this situation).
People currently enrolled in a specific study called PCI-32765LYM1002 who are actively receiving either ibrutinib alone or ibrutinib combined with a medicine called nivolumab.
People whose treating doctor believes the benefits of continuing ibrutinib (alone or with nivolumab) outweigh the potential risks.
People who agree to use effective contraception as required by the trial protocol.
People whose pregnancy test (blood or urine) comes back negative at the screening stage.
Who may not be able to join:
People who need to take blood-thinning medicines such as warfarin or similar vitamin K antagonist medications.
People who need to take certain strong medications that affect how the body processes drugs (known as strong CYP3A4/5 inhibitors), unless the trial sponsor has previously given approval (confirm with trial site).
People who have any health condition or personal circumstance that, in their doctor's opinion, could put them at significant risk, affect the study results, or seriously interfere with their ability to take part.
Important: Always verify eligibility with the trial site directly before applying.
Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.
This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.
🇦🇷 Argentina
🇦🇺 Australia
🇧🇪 Belgium
🇧🇷 Brazil
🇨🇦 Canada
🇨🇳 China
🇨🇴 Colombia
🇨🇿 Czechia
🇫🇷 France
🇩🇪 Germany
🇬🇷 Greece
🇭🇺 Hungary
🇮🇪 Ireland
🇮🇱 Israel
🇮🇹 Italy
🇯🇵 Japan
🇲🇽 Mexico
🇳🇱 Netherlands
🇵🇱 Poland
🇵🇹 Portugal
Puerto Rico
🇷🇺 Russia
🇰🇷 South Korea
🇪🇸 Spain
🇸🇪 Sweden
🇹🇼 Taiwan
Turkey (Türkiye)
🇺🇦 Ukraine
🇬🇧 United Kingdom
🇺🇸 United States
8 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Number of participants affected by an adverse event
Can't join this trial?
Expanded access pathways
If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.